Poltreg S.A. PTG.WA · Stock Open Poltreg S.A. in new tab
Poltreg S.A. Analysis (PTG.WA)
Is Poltreg S.A. a good investment? Poltreg S.A. (PTG.WA) is currently trading at 20.10 PLN.
Earnings Schedule: Poltreg S.A. is expected to release its next earnings report on Nov. 18, 2026.
Investor FAQ
Does Poltreg S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Poltreg S.A.?
Poltreg S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -4.98.
Company Profile
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient's damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.
Community Discussion